本研究目的是了解藥癮C型肝炎感染者，在美沙冬維持療法與C型肝炎治療之情形，並探討美沙冬維持療法是否提升C型肝炎治療之順從性。本研究透過衛生福利部「替代治療作業管理系統」及醫院所屬「醫療管理系統」之次級資料庫進行分析。針對2017-2020年本國籍，於中部某地區教學醫院曾參與美沙冬維持治療合併C型肝炎感染者，藉由卡方、t-test、複迴歸分析背景變項與治療的關係；而美沙冬參與天數、美沙冬服藥順從性、C型肝炎全口服直接作用抗病毒藥物(directly acting antivirals, DAAs)參與天數，進行相關分析，分析美沙冬參與天數與美沙冬及C型肝炎服藥順從性關係。
本研究共分析169人，結果顯示，在患者第一次加入美沙冬維持治療時，其服藥順從性與婚姻狀態有顯著差異；患者是否有愛滋在第一次加入美沙冬維持治療時有差異；美沙冬維持治療服藥順從性是否提升C型肝炎治療順從性則無顯著差異。研究建議應鼓勵藥癮者C型肝炎感染者治療C肝，相關醫療人員亦需積極治療藥癮者C型肝炎患者，讓患者可以在治療藥癮的同時C肝也被治癒。

In this study is examine whether methadone maintenance therapy(MMT) increased hepatitis C therapy adherence among a cohort of hepatitis C people who inject drugs (PWIDs). This study analyzed the secondary database. There were 169 PWIDs participants who accessed MMT from 2007-2020 and participated the hepatitis C treatment in the same hospital.We used the Chi-Squared Test, t-test and multiple regression analysis to examined relationship between demographic variables and hepatitis C treatment and medication adherence of methadone.
In this study showed that the adherence of the patients with methadone treatment and the marital status were significantly different when they first joined the methadone maintenance treatment; the patients had AIDS were significantly difference when they first joined methadone maintenance therapy; there was no significant difference between the adherence of methadone treatment and the adherence of treatment with hepatitis C. The results of this study suggested that health staffs should encourage PWIDs with hepatitis C treat hepatitis C positively.

一、中文文獻
吳慧敏、楊雯雯、劉嘉玲、鄭國本、陳時中、陳建仁、蒲若芳（2021）。台灣 2025 年 C 肝消除的策略與進度。台灣公共衛生雜誌，40（1）， 1-4。
李思賢（2008）。減少傷害緣起與思維：以美沙冬療法做為防制愛滋感染、減少犯罪與海洛因戒治之策略的研究發現。刑事政策與犯罪研究論文集，11。89-109。
周孫元（2009a）。美沙冬替代療法治療海洛因成癮之成效及影響治療持續性之相關因子探討。社團法人台灣成癮科學學會：2009年年會暨學術研討會，苗栗縣。
周孫元（2009b）。美沙冬替代療法在海洛因成癮個案之療效評估-以桃園療養院為例。管制藥品簡訊，40。
林滄耀、李世凱、陳瑾樺、吳聖良（2005）。某療養院海洛因依賴住院病患C型肝炎盛行率及其相關因素研究。醫保研究雜誌，1（1），21-30。
法務部（2018）。毒品案件性別分析。於2021年1月5日取自https://antidrug.moj.gov.tw/lp-1197-2.html
邱珠敏、孫芝佩、周玉民、楊靖慧（2017）。臺灣病毒性 C 型肝炎流行情形及預防策略。台灣醫學，21(6), 582-588。
張柏宏、黃鈴晃（2011）。毒品防制學（365-398頁）。臺北市：五南。
陳乃釧、楊延壽、李之微（2009）。美沙冬替代療法。基層醫學， 24（2），61-65。
陳時中、諶立中、鄭淑心、洪嘉璣、許育華 （2017）。伴你，找回人生主控權－替代治療十周年特輯。臺北市：衛生福利部。
黃茂軒、楊凱鈞（2020）。海洛因成癮的治療策略。臨床醫學月刊，85（5），271-275。
廖定烈、陳保中（2014）。美沙冬門診患者感染症及肝功能狀況。台灣法醫學誌，6（1）。17-22。
臺灣高等檢察署（2020）。2020年國內毒品情勢快速分析年報。於2020年11月15日取自https://www.tph.moj.gov.tw/4421/4599/4603/749677/788487/
劉鳳樟 、張恩書 、黃秀鳳 、李瑞珍（2021）。Maviret於慢性C型肝炎病患之療效研究。南臺灣醫學雜誌，17（1），7-12。
衛生署（2012）。鴉片類成癮物質替代治療臨床指引。於2020年11月10日取自https://dep.mohw.gov.tw/DOMHAOH/cp-4097-43565-107.html
衛生福利部（2005）。減害策略觀念之說明。於2020年10月12日取自https://www.cdc.gov.tw/Category/ListContent/TKG-8nvtp3Y1fHxeMxWJ1Q?uaid=JMYuS2_UnDtkF368Tbj0IA
衛生福利部食品藥物管理署（2020a）。107年全國物質使用調查結果報告。臺北市：衛生福利部食品藥物管理署。
衛生福利部食品藥物管理署（2020b）。108年藥物濫用案件暨檢驗統計資料年報。於2020年12月12日取自https://www.fda.gov.tw/tc/site.aspx?sid=10776
衛生福利部食品藥物管理署（2021）。109年10月藥物濫用案件暨檢驗統計資料。於2021年1月31日取自https://www.fda.gov.tw/TC/site.aspx?sid=10778
衛生福利部疾病管制署（2012）。愛滋病防治工作手冊（第三版）。於2020年11月8日取自https://www.cdc.gov.tw/InfectionReport/Info/SVtdjRgESOT_EwbAhjIJ4g?infoId=ACcttx_DwlsfGuFyX85gJw
衛生福利部疾病管制署（2017）。我國現階段C肝篩檢、治療及防治現況書面報告。於2020年12月5日取自https://dep.mohw.gov.tw/CLU/fp-619-46783-122.html
衛生福利部疾病管制署（2018）。急性C型肝炎疾病介紹。於2020年12月5日取自https://www.cdc.gov.tw/Category/Page/LN5rPgM5D4MUEDitiTWZfw
衛生福利部疾病管制署（2019）。愛滋病統計資料。於2020年11月13日取自https://www.cdc.gov.tw/Category/Page/rCV9N1rGUz9wNr8lggsh2Q
林綺英、衛漢庭、鄭健禹、陳亮妤（2021）。愛滋病毒感染者合併物質使用疾患（海洛因及安非他命）治療照護原則。於2021年3月8日取自http://www.aids-care.org.tw/journal/treatment.asp
謝明鴻（2012）。海洛因成癮者持續接受美沙冬維持治療之預測因子研究（未出版之博士論文）。中山醫學大學醫學研究所，臺中市。
顏銘漢、薛文傑、林可寰（2009）。海洛因成癮與戒治。家庭醫學與基層醫療, 24（4）, 131-137。
二、外文文獻
Akiyama, M. J., Lipsey, D., Heo, M., Agyemang, L., Norton, B. L., Hidalgo, J., ... & Litwin, A. H. (2020). Low hepatitis C reinfection following direct-acting antiviral therapy among people who inject drugs on opioid agonist therapy. Clinical Infectious Diseases, 70(12), 2695-2702.
Ansaldi, F., Orsi, A., Sticchi, L., Bruzzone, B., & Icardi, G. (2014). Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World journal of gastroenterology: WJG, 20(29), 9633.
Asher, A. K., Portillo, C. J., Cooper, B. A., Dawson-Rose, C., Vlahov, D., & Page, K. A. (2016). Clinicians’ views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs. Substance Use and Misuse, 51, 1218–1223.
Brown, M. T., & Bussell, J. K. (2011, April). Medication adherence: WHO cares?. In Mayo clinic proceedings (Vol. 86, No. 4, pp. 304-314). Elsevier.
Brown, M. T., Bussell, J., Dutta, S., Davis, K., Strong, S., & Mathew, S. (2016). Medication adherence: truth and consequences. The American journal of the medical sciences, 351(4), 387-399.
Centers for Control and Prevent (2019). Surveillance for Viral Hepatitis United States, 2017. Retrieved from https://www.cdc.gov/hepatitis/statistics/2017surveillance/index.htm
Chao, E., Hung, C. C., Lin, C. P., Ku, Y. C. J., Ain, Q. U., Metzger, D. S., & Lee, T. S. H. (2020). Adherence among HIV-positive injection drug users undergoing methadone treatment in Taiwan. BMC psychiatry, 20(1), 1-8.
Chen, C. H., Yang, P. M., Huang, G. T., Lee, H. S., Sung, J. L., & Sheu, J. C. (2007). Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. Journal of the Formosan Medical Association, 106(2), 148-155.
Chou, Y. C., Shih, S. F., Tsai, W. D., Chiang-shan, R. L., Xu, K., & Lee, T. S. H. (2013). Improvement of quality of life in methadone treatment patients in northern Taiwan: a follow-up study. BMC psychiatry, 13(1), 1-8.
Cunningham, E. B., Hajarizadeh, B., Amin, J., Litwin, A. H., Gane, E., Cooper, C., ... & Grebely, J. (2020). Adherence to once-daily and twice-daily direct-acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy. Clinical infectious diseases, 71(7), e115-e124.
Davstad, I., Stenbacka, M., Anders Leifman, M. S. E., Beck, O., Korkmaz, S., & Romelsjo, A. (2007). Patterns of illicit drug use and retention in a methadone program: a longitudinal study. Journal of Opioid Management, 3(1), 27-34.
Demaret, I., Lemaître, A., & Ansseau, M. (2013). L'héroïne. Revue medicale de Liege, 68(5-6), 287.
Edlin, B. R. (2002). Prevention and treatment of hepatitis C in injection drug users. Hepatology, 36(S1), S210-S219.
Farmani, F., Farhadi, H., & Mohammadi, Y. (2018). Associated factors of maintenance in patients under treatment with methadone: a comprehensive systematic review and meta-analysis. Addiction & health, 10(1), 41.
Grebely, J., Alavi, M., Micallef, M., Dunlop, A. J., Balcomb, A. C., Phung, N., ... & ETHOS Study Group. (2016). Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction, 111(2), 311-319.
Harm Reduction International (2020).What is harm reduction? Retrieved from https://www.hri.global/what-is-harm-reduction
Heinz, A. J., Wu, J., Witkiewitz, K., Epstein, D. H., & Preston, K. L. (2009). Marriage and relationship closeness as predictors of cocaine and heroin use. Addictive behaviors, 34(3), 258-263.
Hosztafi, S. (2011). Heroin addiction. Acta pharmaceutica Hungarica, 81(4), 173-183.
Jimmy, B., & Jose, J. (2011). Patient medication adherence: measures in daily practice. Oman medical journal, 26(3), 155.
Lee, T. S. H., Shen, H. C., Wu, W. H., Huang, C. W., Yen, M. Y., Wang, B. E., ... & Liu, Y. L. (2011). Clinical characteristics and risk behavior as a function of HIV status among heroin users enrolled in methadone treatment in northern Taiwan. Substance Abuse Treatment, Prevention, and Policy, 6(1), 1-7.
Liu, H. W., Hsu, C. C., Lin, L. L., & Wu, W. H. (2009). Methadone Maintenance Treatment in a General Hospital. 臺灣精神醫學, 23(3), 215-222.
Liu JY, Lin HH, Liu YC, et al. Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008; 46(11): 1761-1768.
Mukherjee, R., Burns, A., Rodden, D., Chang, F., Chaum, M., Garcia, N., ... & Niemz, A. (2015). Diagnosis and management of hepatitis C virus infection. Journal of laboratory automation, 20(5), 519-538.
Ng MH, Chou JY, Chang TJ, et al. High prevalence but low awareness of hepatitis C virus infection among heroin users who received methadone maintenance therapy in Taiwan. Addictive behaviors 2013; 38(4): 2089-2093.
Omata, M., Kanda, T., Wei, L., Yu, M. L., Chuang, W. L., Ibrahim, A., ... & Sharma, B. C. (2016). APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatology international, 10(5), 681-701.
Osterberg, L., & Blaschke, T. (2005). Adherence to medication. New England journal of medicine, 353(5), 487-497.
Pawlotsky, J. M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., ... & European Association for the Study of the Liver. (2020). EASL recommendations on treatment of hepatitis C: final update of the series☆. Journal of Hepatology, 73(5), 1170-1218.
Poynard, T., Yuen, M. F., Ratzin, V., & Lai, C. L. (2003). Viral hepatitis C. The Lancet, 362(9401), 2095-2100.
Senbanjo, R., Tipping, T., Hunt, N., & Strang, J. (2012). Injecting drug use via femoral vein puncture: preliminary findings of a point-of-care ultrasound service for opioid-dependent groin injectors in treatment. Harm reduction journal, 9(1), 1-8.
Sun, H. Y., Ko, W. C., Tsai, J. J., Lee, H. C., Liu, C. E., Wong, W. W., ... & Hung, C. C. (2009). Seroprevalence of chronic hepatitis B virus infection among taiwanese human immunodeficiency virus type 1-positive persons in the era of nationwide hepatitis B vaccination. American Journal of Gastroenterology, 104(4), 877-884.
Sylvestre, D. L., & Clements, B. J. (2007). Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. European journal of gastroenterology & hepatology, 19(9), 741-747.
Tai, C. M., Yen, Y. C., Bair, M. J., Tseng, C. H., Chang, T. T., Huang, C. F., ... & Huang, J. F. (2019). Integrated care for methadone maintenance patients with hepatitis C virus infection. The Kaohsiung journal of medical sciences, 35(8), 501-507.
Ti, L., Socías, M. E., Wood, E., Milloy, M. J., Nosova, E., DeBeck, K., ... & Hayashi, K. (2018). The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs. PloS one, 13(3), e0194162.
Timko, C., Schultz, N. R., Cucciare, M. A., Vittorio, L., & Garrison-Diehn, C. (2016). Retention in medication-assisted treatment for opiate dependence: a systematic review. Journal of addictive diseases, 35(1), 22-35.
United Nation Office on Drugs and Crime (2020).World Drug Report, 2020. Retrieved from https://wdr.unodc.org/wdr2020/index.html
Verthein, U., Bonorden‐Kleij, K., Degkwitz, P., Dilg, C., Köhler, W. K., Passie, T., ... & Haasen, C. (2008). Long‐term effects of heroin‐assisted treatment in Germany. Addiction, 103(6), 960-966.
Walsh, N., Verster, A., Rodolph, M., & Akl, E. A. (2014). WHO guidance on the prevention of viral hepatitis B and C among people who inject drugs. International Journal of Drug Policy, 25(3), 363-371.
World Health Organization(2020). Hepatitis C：fact sheet, 27 July 2020.Retrieved from https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
Yu, M. L., & Chuang, W. L. (2009). Treatment of chronic hepatitis C in Asia: when East meets West. Journal of gastroenterology and hepatology, 24(3), 336-345.